BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

416 related articles for article (PubMed ID: 25989603)

  • 1. Intracellular siRNA delivery dynamics of integrin-targeted, PEGylated chitosan-poly(ethylene imine) hybrid nanoparticles: A mechanistic insight.
    Ragelle H; Colombo S; Pourcelle V; Vanvarenberg K; Vandermeulen G; Bouzin C; Marchand-Brynaert J; Feron O; Foged C; Préat V
    J Control Release; 2015 Aug; 211():1-9. PubMed ID: 25989603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficient siRNA delivery and tumor accumulation mediated by ionically cross-linked folic acid-poly(ethylene glycol)-chitosan oligosaccharide lactate nanoparticles: for the potential targeted ovarian cancer gene therapy.
    Li TS; Yawata T; Honke K
    Eur J Pharm Sci; 2014 Feb; 52():48-61. PubMed ID: 24178005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Delivery of siRNA targeting tumor metabolism using non-covalent PEGylated chitosan nanoparticles: Identification of an optimal combination of ligand structure, linker and grafting method.
    Corbet C; Ragelle H; Pourcelle V; Vanvarenberg K; Marchand-Brynaert J; Préat V; Feron O
    J Control Release; 2016 Feb; 223():53-63. PubMed ID: 26699426
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chitosan nanoparticles for siRNA delivery: optimizing formulation to increase stability and efficiency.
    Ragelle H; Riva R; Vandermeulen G; Naeye B; Pourcelle V; Le Duff CS; D'Haese C; Nysten B; Braeckmans K; De Smedt SC; Jérôme C; Préat V
    J Control Release; 2014 Feb; 176():54-63. PubMed ID: 24389132
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ScFv-decorated PEG-PLA-based nanoparticles for enhanced siRNA delivery to Her2⁺ breast cancer.
    Dou S; Yang XZ; Xiong MH; Sun CY; Yao YD; Zhu YH; Wang J
    Adv Healthc Mater; 2014 Nov; 3(11):1792-803. PubMed ID: 24947820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. siRNA delivery with chitosan nanoparticles: Molecular properties favoring efficient gene silencing.
    Malmo J; Sørgård H; Vårum KM; Strand SP
    J Control Release; 2012 Mar; 158(2):261-8. PubMed ID: 22119955
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An inhalable β₂-adrenoceptor ligand-directed guanidinylated chitosan carrier for targeted delivery of siRNA to lung.
    Luo Y; Zhai X; Ma C; Sun P; Fu Z; Liu W; Xu J
    J Control Release; 2012 Aug; 162(1):28-36. PubMed ID: 22698944
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of carrier-mediated siRNA delivery: lessons for the design of a stem-loop qPCR-based approach for quantification of intracellular full-length siRNA.
    Colombo S; Nielsen HM; Foged C
    J Control Release; 2013 Mar; 166(3):220-6. PubMed ID: 23313963
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer-targeted MDR-1 siRNA delivery using self-cross-linked glycol chitosan nanoparticles to overcome drug resistance.
    Yhee JY; Song S; Lee SJ; Park SG; Kim KS; Kim MG; Son S; Koo H; Kwon IC; Jeong JH; Jeong SY; Kim SH; Kim K
    J Control Release; 2015 Jan; 198():1-9. PubMed ID: 25481438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cellular uptake mechanism and knockdown activity of siRNA-loaded biodegradable DEAPA-PVA-g-PLGA nanoparticles.
    Benfer M; Kissel T
    Eur J Pharm Biopharm; 2012 Feb; 80(2):247-56. PubMed ID: 22085653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted delivery of small interfering RNA to colon cancer cells using chitosan and PEGylated chitosan nanoparticles.
    Rudzinski WE; Palacios A; Ahmed A; Lane MA; Aminabhavi TM
    Carbohydr Polym; 2016 Aug; 147():323-332. PubMed ID: 27178938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chitosan-based nanoparticles for survivin targeted siRNA delivery in breast tumor therapy and preventing its metastasis.
    Sun P; Huang W; Jin M; Wang Q; Fan B; Kang L; Gao Z
    Int J Nanomedicine; 2016; 11():4931-4945. PubMed ID: 27729789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The influence of polymeric properties on chitosan/siRNA nanoparticle formulation and gene silencing.
    Liu X; Howard KA; Dong M; Andersen MØ; Rahbek UL; Johnsen MG; Hansen OC; Besenbacher F; Kjems J
    Biomaterials; 2007 Feb; 28(6):1280-8. PubMed ID: 17126901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic delivery of therapeutic small interfering RNA using a pH-triggered amphiphilic poly-L-lysine nanocarrier to suppress prostate cancer growth in mice.
    Guo J; Cheng WP; Gu J; Ding C; Qu X; Yang Z; O'Driscoll C
    Eur J Pharm Sci; 2012 Apr; 45(5):521-32. PubMed ID: 22186295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PEGylated carboxymethyl chitosan/calcium phosphate hybrid anionic nanoparticles mediated hTERT siRNA delivery for anticancer therapy.
    Xie Y; Qiao H; Su Z; Chen M; Ping Q; Sun M
    Biomaterials; 2014 Sep; 35(27):7978-91. PubMed ID: 24939077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibiting hepatic gluconeogenesis by chitosan lactate nanoparticles containing CRTC2 siRNA targeted by poly(ethylene glycol)-glycyrrhetinic acid.
    Rastegari A; Mottaghitalab F; Dinarvand R; Amini M; Arefian E; Gholami M; Atyabi F
    Drug Deliv Transl Res; 2019 Jun; 9(3):694-706. PubMed ID: 30825078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted decationized polyplexes for siRNA delivery.
    Novo L; Takeda KM; Petteta T; Dakwar GR; van den Dikkenberg JB; Remaut K; Braeckmans K; van Nostrum CF; Mastrobattista E; Hennink WE
    Mol Pharm; 2015 Jan; 12(1):150-61. PubMed ID: 25384057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pancreatic cancer therapy by systemic administration of VEGF siRNA contained in calcium phosphate/charge-conversional polymer hybrid nanoparticles.
    Pittella F; Miyata K; Maeda Y; Suma T; Watanabe S; Chen Q; Christie RJ; Osada K; Nishiyama N; Kataoka K
    J Control Release; 2012 Aug; 161(3):868-74. PubMed ID: 22580114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimising the self-assembly of siRNA loaded PEG-PCL-lPEI nano-carriers employing different preparation techniques.
    Endres T; Zheng M; Beck-Broichsitter M; Samsonova O; Debus H; Kissel T
    J Control Release; 2012 Jun; 160(3):583-91. PubMed ID: 22525320
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of antibody-modified chitosan nanoparticles for the targeted delivery of siRNA across the blood-brain barrier as a strategy for inhibiting HIV replication in astrocytes.
    Gu J; Al-Bayati K; Ho EA
    Drug Deliv Transl Res; 2017 Aug; 7(4):497-506. PubMed ID: 28315051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.